Erratum to ‘Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts’ (Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts (2008) 42(1) (200–211), (S8756328207006928), (10.1016/j.bone.2007.09.044));Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

Bone

Volumn 42, Issue 1, 2008, Pages 200-211

  Fuller, Karen ^a   Lawrence, Kevin M ^a   Ross, Jade L ^a   Grabowska, Urszula B ^b   Shiroo, Masahiro ^b   Samuelsson, Bertil ^b   Chambers, Timothy J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MEDIVIR AB   (Sweden)

Author keywords

Bone resorption; Cathepsin K; Growth factors; Osteoclast

Indexed keywords

ALENDRONIC ACID; BAFILOMYCIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN; MV 061194; OSTEOCALCIN; PAMIDRONIC ACID; PROTON; RECOMBINANT ENZYME; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DEMINERALIZATION; BONE MATRIX; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; OSSIFICATION; OSTEOCLAST; PROTEIN DEGRADATION; PROTEIN SECRETION; SUPERNATANT;

EID: 37349065426     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2020.115354     Document Type: Erratum

References (69)

1. Adami A., Supronik J., Hala T., Brown J., Garnero P., Haemmerle S., et al. Effect of one year treatment with the cathepsin K inhibitor balicatib on bone mineral density in postmenopausal women with osteopenia. J Bone Miner Res 21 Suppl 1 (2006) 1085
2. Bikle D.D., Sakata T., Leary C., Elalieh H., Ginzinger D., Rosen C.J., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17 (2002) 1570-1578
3. Brown J.P., Delmas P.D., Malaval L., Edouard C., Chapuy M.C., and Meunier P.J. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1 (1984) 1091-1093
4. C Jerome M.M., and Gamse R. AAE581, a novel cathepsin K inhibitor, protects against ovariectomy-induced bone loss in non-human primates, in part by stimulation of periosteal bone formation. J Bone Miner Res 20 Suppl 1 (2005) S46
5. Chambers T.J. The direct and indirect effects of estrogen on bone formation. Advances in organ biology (1998), JAI Press Inc., Stamford, CT
6. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J Pathol 192 (2000) 4-13
7. Chambers T.J., McSheehy P.M., Thomson B.M., and Fuller K. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 116 (1985) 234-239
8. Charles P., Poser J.W., Mosekilde L., and Jensen F.T. Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest 76 (1985) 2254-2258
9. Chesnut III C.H., and Harris S.T. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int 3 Suppl 3 (1993) S17-S19
10. Chow J.W., Badve S., and Chambers T.J. Bone formation is not coupled to bone resorption in a site-specific manner in adult rats. Anat Rec 236 (1993) 366-372
11. Chow J.W., Badve S., and Chambers T.J. A comparison of microanatomic basis for coupling between bone formation and bone resorption in man and the rat. Bone 14 (1993) 355-360
12. Everts V., Delaisse J.M., Korper W., Jansen D.C., Tigchelaar-Gutter W., Saftig P., et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17 (2002) 77-90
13. Everts V., Korper W., Hoeben K.A., Jansen I.D., Bromme D., Cleutjens K.B., et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21 (2006) 1399-1408
14. Farley J.R., Tarbaux N., Murphy L.A., Masuda T., and Baylink D.J. In vitro evidence that bone formation may be coupled to resorption by release of mitogen(s) from resorbing bone. Metabolism 36 (1987) 314-321
15. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 (2003) 1216-1226
16. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23 (2002) 824-854
17. Stroup G., C.J., Yamashita D.S., and Kumar S. Histomorphometric and biochemical evidence for a cortical bone-forming effect of a cathepsin K inhibitor in ovariectomized cynomolgus monkeys. J Bone Miner Res 20 Suppl 1 (2005) S80
18. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273 (1998) 32347-32352
19. Gasser J.A. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. Curr Opin Pharmacol 6 (2006) 313-318
20. Gelb B.D., Shi G.P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996) 1236-1238
21. Godat E., Lecaille F., Desmazes C., Duchene S., Weidauer E., Saftig P., et al. Cathepsin K: a cysteine protease with unique kinin-degrading properties. Biochem J 383 (2004) 501-506
22. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14 (1999) 1654-1663
23. Grabowska U., Chambers T.J., and Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Dev 8 (2005) 619-630
24. Greenspan S.L., Holland S., Maitland-Ramsey L., Poku M., Freeman A., Yuan W., et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 108 (1996) 230-238
25. Gruber H.E., Ivey J.L., Baylink D.J., Matthews M., Nelp W.B., Sisom K., et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33 (1984) 295-303
26. Halleen J.M., Raisanen S., Salo J.J., Reddy S.V., Roodman G.D., Hentunen T.A., et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 274 (1999) 22907-22910
27. Harris S.T., Neer R.M., Segre G.V., Petkau A.J., Tully III G.L., Daly M., et al. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease. J Clin Endocrinol Metab 55 (1982) 1100-1117
28. Hattner R., Epker B.N., and Frost H.M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206 (1965) 489-490
29. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., and Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261 (1986) 12665-12674
30. Hayden J.M., Mohan S., and Baylink D.J. The insulin-like growth factor system and the coupling of formation to resorption. Bone 17 (1995) 93S-98S
31. Hou W.S., Li Z., Buttner F.H., Bartnik E., and Bromme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 384 (2003) 891-897
32. Huiskes R., Ruimerman R., van Lenthe G.H., and Janssen J.D. Effects of mechanical forces on maintenance and adaptation of form in trabecular bone. Nature 405 (2000) 704-706
33. Indech M., and Jowsey J. Secondary hyperparathyroidism produced in kittens repeatedly given porcine calcitonin. Endocrinology 88 (1971) 1489-1496
34. Itabashi A., Kurata N., Sugita Y., and Kawai Y. A novel cathepsin K inhibitor, increases serum intact PTH beyond diurnal patterns following a 14-daily administration in Japanese postmenopausal women. J Bone Miner Res 21 Suppl 1 (2006) 1086
35. Jowsey J., Riggs B.L., Kelly P.J., Hoffman D.L., and Bordier P. The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate. J Lab Clin Med 78 (1971) 574-584
36. Kafienah W., Bromme D., Buttle D.J., Croucher L.J., and Hollander A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 331 Pt 3 (1998) 727-732
37. Kirstein B., Chambers T.J., and Fuller K. Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98 (2006) 1085-1094
38. Kiviranta R., Morko J., Alatalo S.L., NicAmhlaoibh R., Risteli J., Laitala-Leinonen T., et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36 (2005) 159-172
39. Landman J.O., Schweitzer D.H., Frolich M., Hamdy N.A., and Papapoulos S.E. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. J Clin Endocrinol Metab 80 (1995) 524-528
40. Le Roith D. The insulin-like growth factor system. Exp Diabesity Res 4 (2003) 205-212
41. Le Roith D., Bondy C., Yakar S., Liu J.L., and Butler A. The somatomedin hypothesis: 2001. Endocr Rev 22 (2001) 53-74
42. Lean J.M., Mackay A.G., Chow J.W., and Chambers T.J. Osteocytic expression of mRNA for c-fos and IGF-I: an immediate early gene response to an osteogenic stimulus. Am J Physiol 270 (1996) E937-E945
43. Li C.Y., Jepsen K.J., Majeska R.J., Zhang J., Ni R., Gelb B.D., et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21 (2006) 865-875
44. Ljusberg J., Wang Y., Lang P., Norgard M., Dodds R., Hultenby K., et al. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280 (2005) 28370-28381
45. Martin T.J., and Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11 (2005) 76-81
46. Mohan S., Jennings J.C., Linkhart T.A., and Baylink D.J. Primary structure of human skeletal growth factor: homology with human insulin-like growth factor-II. Biochim Biophys Acta 966 (1988) 44-55
47. Montenez J.P., Delaisse J.M., Tulkens P.M., and Kishore B.K. Increased activities of cathepsin B and other lysosomal hydrolases in fibroblasts and bone tissue cultured in the presence of cysteine proteinases inhibitors. Life Sci 55 (1994) 1199-1208
48. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
49. Nicolas V., Prewett A., Bettica P., Mohan S., Finkelman R.D., Baylink D.J., et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 78 (1994) 1011-1016
50. Ochi Y., Yamada H., Kawada K., Nakanishi Y., Mori H., Kayasuga R., et al. Orally active cathepsin K inhibitor potently and rapidly improved both bone mineral density and strength of not only lumbar vertebra but also femoral neck in ovariectomized cynomolgus monkeys. J Bone Miner Res 21 Suppl 1 (2006) F234
51. Papanastasiou P., Ortmann C., Olson M., Vigneron A., and Trechsel U. Effect of three month treatment with the cathepsin K inhibitor balicatib on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation. J Bone Miner Res 21 Suppl 1 (2006) 1223
52. Parfitt A.M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4 (1982) 1-6
53. Pennypacker A., Rodan S., Masarachia P., Rodan G., and Kimmel D. Bone effects of a cathepsin K inhibitor in the adult estrogen deficient rabbit. J Bone Miner Res 21 (2006) SU383 [supplement]
54. Pfeilschifter J., and Mundy G.R. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A 84 (1987) 2024-2028
55. Poole K.E., and Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5 (2005) 612-617
56. Riggs B.L., Tsai K.S., and Mann K.G. Effect of acute increases in bone matrix degradation on circulating levels of bone-Gla protein. J Bone Miner Res 1 (1986) 539-542
57. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 95 (1998) 13453-13458
58. Seyedin S.M., Thompson A.Y., Bentz H., Rosen D.M., McPherson J.M., Conti A., et al. Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J Biol Chem 261 (1986) 5693-5695
59. Silver I.A., Murrills R.J., and Etherington D.J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 175 (1988) 266-276
60. Singer F.R., Clemens T.L., Eusebio R.A., and Bekker P.J. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83 (1998) 1906-1910
61. Stroup G., Dare L., Vasko-Moser J., Hoffman S., and Kumar S. Repeat daily dosing with a highly potent inhibitor of cathepsin K results in significant, transient elevation of plasma PTH in cynomolgus monkeys. J Bone Miner Res 21 Suppl 1 (2006) SA236
62. Sundquist K., Lakkakorpi P., Wallmark B., and Vaananen K. Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorption. Biochem Biophys Res Commun 168 (1990) 309-313
63. Tobias J.H., Chow J.W., and Chambers T.J. Opposite effects of insulin-like growth factor-I on the formation of trabecular and cortical bone in adult female rats. Endocrinology 131 (1992) 2387-2392
64. Vaananen H., Zhao K., Mulari H., and Halleen M. The cell biology of osteoclast function. J Cell Sci 113 Pt 3 (2000) 377-381
65. Vaaraniemi J., Halleen J.M., Kaarlonen K., Ylipahkala H., Alatalo S.L., Andersson G., et al. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 19 (2004) 1432-1440
66. Vukicevic S., Latin V., Chen P., Batorsky R., Reddi A.H., and Sampath T.K. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high affinity binding to basement membranes. Biochem Biophys Res Commun 198 (1994) 693-700
67. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 242 (1988) 1528-1534
68. Yamane H., Sakai A., Mori T., Tanaka S., Katae Y., Menuki Y., et al. Inhibitor of cathepsin K (ONO-KK1-300-01) does not disturb the anabolic action of PTH on bone in the ovariectomized mice. J Bone Miner Res 21 Suppl 1 (2006) SA238
69. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4 (2006) 111-121